Technology

SpotitEarly advances cancer detection through its innovation pipeline, combining AI, automation, and VOC biomarker research. Enhanced data collection improves predictive accuracy and automation scales testing capacity. Together, these breakthroughs pave the way for a more accurate, accessible, and scalable future in early diagnosis.

The cancer detection industry is undergoing rapid transformation, driven by demand for earlier diagnosis, multi-cancer technologies, and AI integration. This article explores the trends shaping the field, from liquid biopsy development to accessibility challenges, and highlights how SpotitEarly addresses these gaps. With a bio-AI breath test platform detecting VOCs at early stages, SpotitEarly combines accuracy, accessibility, and transparency to help lead the cancer detectio

Data privacy is central to SpotitEarly’s mission. As a HIPAA-compliant company, we implement strict safeguards to protect every piece of patient information, from breath sample analysis to medical background and AI-driven results. This article outlines how our layered approach combines encrypted storage, secure databases, strict access controls, and continuous monitoring. At SpotitEarly, innovative cancer detection goes hand in hand with rigorous healthcare data protection.

Cancer screening today is effective but limited, with most cancers lacking recommended tests. This article compares traditional methods like mammography and colonoscopy with new liquid biopsy approaches and introduces SpotitEarly’s breath-based test. By detecting volatile organic compounds (VOCs) through a bio-hybrid platform that combines canine olfaction with AI, SpotitEarly is advancing a non-invasive, accurate solution that complements current screening and expands early

Breath analysis is transforming the landscape of early cancer detection. By identifying volatile organic compounds (VOCs) in exhaled air, this non-invasive method can reveal disease indicators long before symptoms appear. This article explains the science behind breath-based biomarkers, how SpotitEarly integrates them with canine scent detection and AI, and why this approach offers accuracy, comfort, and scalability for global screening.

SpotitEarly welcomed Dr. J. Leonard “Len” Lichtenfeld as its first Chief Medical Officer to help accelerate early cancer detection. This article outlines his career leadership at the American Cancer Society, his vision for catching cancer earlier, and his priorities at SpotitEarly: advancing rigorous clinical research, building partnerships across healthcare, and securing the resources to scale access to innovative, non‑invasive screening worldwide.

SpotitEarly’s LUCID bio-hybrid platform unites the natural sensitivity of trained detection dogs with the precision of artificial intelligence. This article explores how the system captures and analyzes breath samples, integrates biological and technological strengths, and delivers accurate, scalable early cancer detection. Learn how LUCID is redefining what’s possible in non-invasive cancer screening.

The recent Rainbow clinical study, published in Nature Scientific Reports, showcases SpotitEarly’s extraordinary success. It shows SpotitEarly is able to detect cancer at early stages with sensitivity rates exceeding 90% for multiple cancers, including those with no standard screening options available today. This breakthrough positions SpotitEarly as a world leader in early disease detection technology.

Artificial intelligence is at the core of SpotitEarly’s bio-hybrid AI platform, refining and validating results from canine scent detection to ensure accuracy and scalability. This article explores how AI models process complex data, integrate it with clinical workflows, and evolve it over time. By combining canine’s abilities with cutting-edge machine learning, SpotitEarly aims to make early cancer screening more precise, accessible, and widely adopted.

Dogs possess an extraordinary sense of smell — capable of detecting volatile organic compounds linked to cancer at concentrations humans cannot perceive. This article will explain the biology of canine olfaction, the research behind scent-based cancer detection, and how SpotitEarly plans to train dogs as part of a hybrid platform with AI to make early, non-invasive cancer screening possible on a global scale.

SpotitEarly is developing a revolutionary approach to early cancer detection, combining the natural scent detection abilities of trained dogs with advanced AI analysis. This article introduces the company’s mission, technology, and vision for a future where non-invasive, accurate, and accessible screening is available worldwide. Learn how this hybrid platform aims to make early detection more effective and widely adopted.

As SpotitEarly’s COO and co-founder, Udi Bobrovsky oversees the operational and strategic direction of the company’s early cancer detection platform. In this interview, he shares how his background in tech entrepreneurship and digital health drives the company’s mission, his approach to scaling a hybrid canine-AI screening system, and why he believes innovation and collaboration are key to transforming cancer detection globally.

At SpotitEarly, we are transforming the way cancer screening works, making it more accessible, accurate and user-friendly. Our innovative breath test is designed to detect cancer early, when survival rates are highest and treatment is most effective. But what will the full testing process look like for patients?

SpotitEarly’s mission is to bring accurate, non-invasive cancer screening to people across the globe. In this post, we explore how our unique bio-AI hybrid approach, combining breath analysis with trained canine detection and artificial intelligence, is making early detection accessible, scalable, and effective. Learn how we’re fighting cancer by reaching more people, earlier, and saving lives.